Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with BCG unresponsiveness and receiving intravesical gemcitabine doxetaxel |
| ||
| Patients with BCG unresponsiveness and radical cystectomy performed |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravesical Solution | Drug | Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence rate | the recurrence rate after intravesical chemotherapy will be calculated | 5 years |
| Progression rate | the progression rate after intravesical chemotherapy will be calculated | 5 years |
| Adverse effects of intravesical chemotherapy | the patients' data will be retrospectively analyzed to investigate the side effects of intravesical chemotherapy | 5 years |
| Intravesical chemotherapy versus radical cystectomy | the long-term cancer specific survival, overal survival, recurrence free survival of patients with similar pathological characteristics and who underwent radical cystectomy and patients who were given intravesical chemotherapy will be compared | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| treatment change | patient transitions from intravesical chemotherapy to other treatment options will be calculated | 5 years |
Not provided
Inclusion Criteria:
- BCG refractory/relapsed/unresponsive or intolerant Who do not want or are not suitable for radical cystectomy
Exclusion Criteria:
- BCG naive A history of multiple cancers Having a radical cystectomy plan
Not provided
Not provided
a multi-center study within the scope of the Turkish Urooncology Association
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Muhammed Selcuk Ozer, Medical Doctor | Contact | +905543078941 | +905543078941 | mseljukozer@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dokuz Eylul University Faculty of Medicine Department of Urology | Izmir | Other (Non U.s.) | 35330 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
|
|
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077143 | Docetaxel |
| ID | Term |
|---|---|
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
Not provided
Not provided